174 related articles for article (PubMed ID: 38702077)
21. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.
Baran R; Feuilhade M; Combernale P; Datry A; Goettmann S; Pietrini P; Viguie C; Badillet G; Larnier C; Czernielewski J
Br J Dermatol; 2000 Jun; 142(6):1177-83. PubMed ID: 10848743
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5 % amorolfine lacquer.
Zhang J; Lu S; Huang H; Li X; Cai W; Ma J; Xi L
Lasers Med Sci; 2016 Sep; 31(7):1391-6. PubMed ID: 27339057
[TBL] [Abstract][Full Text] [Related]
23. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.
Baran R
Br J Dermatol; 2001 Oct; 145 Suppl 60():15-9. PubMed ID: 11777260
[TBL] [Abstract][Full Text] [Related]
24. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.
Haria M; Bryson HM
Drugs; 1995 Jan; 49(1):103-20. PubMed ID: 7705210
[TBL] [Abstract][Full Text] [Related]
25. A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails.
Ehrensberger M; Boal CWC; Brennan J; Barrett J; Makarus J; Callanan S; Spillane E; Patton T
J Mycol Med; 2022 Aug; 32(3):101256. PubMed ID: 35219908
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
27. A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis.
Parekh M; Ramaiah G; Pashilkar P; Ramanujam R; Johnston P; Ilag LL
BMC Complement Altern Med; 2017 Sep; 17(1):464. PubMed ID: 28923039
[TBL] [Abstract][Full Text] [Related]
28. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole.
Haneke E; Tajerbashi M; De Doncker P; Heremans A
Dermatology; 1998; 196(3):323-9. PubMed ID: 9621140
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly.
Lauharanta J
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():41-3. PubMed ID: 1458664
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double-blind, randomized, placebo-controlled multicenter study.
Tietz HJ; Hay R; Querner S; Delcker A; Kurka P; Merk HF
Mycoses; 2013 Jul; 56(4):414-21. PubMed ID: 23586591
[TBL] [Abstract][Full Text] [Related]
31. Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.
Iorizzo M; Hartmane I; Derveniece A; Mikazans I
Skin Appendage Disord; 2016 Feb; 1(3):134-40. PubMed ID: 27171791
[TBL] [Abstract][Full Text] [Related]
32. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%.
Warshaw EM; St Clair KR
J Am Acad Dermatol; 2005 Oct; 53(4):717-20. PubMed ID: 16198805
[TBL] [Abstract][Full Text] [Related]
33. Placebo cure rates in the treatment of onychomycosis.
Gupta AK; Paquet M
J Am Podiatr Med Assoc; 2014 May; 104(3):277-82. PubMed ID: 24901587
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
[TBL] [Abstract][Full Text] [Related]
35. Methylene blue-mediated photodynamic therapy may be superior to 5% amorolfine nail lacquer for non-dermatophyte onychomycosis.
Bowornsathitchai N; Thammahong A; Shoosanglertwijit J; Kitsongsermthon J; Wititsuwannakul J; Asawanonda P; Boontaveeyuwat E
Photodermatol Photoimmunol Photomed; 2021 May; 37(3):183-191. PubMed ID: 33145834
[TBL] [Abstract][Full Text] [Related]
36. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
Baran R; Kaoukhov A
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
[TBL] [Abstract][Full Text] [Related]
37. Short term treatment of dermatophyte onychomycosis with terbinafine.
Goodfield MJ; Andrew L; Evans EG
BMJ; 1992 May; 304(6835):1151-4. PubMed ID: 1392793
[TBL] [Abstract][Full Text] [Related]
38. Topical azole treatments for otomycosis.
Lee A; Tysome JR; Saeed SR
Cochrane Database Syst Rev; 2021 May; 5(5):CD009289. PubMed ID: 34033120
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
Gupta AK; Leonardi C; Stoltz RR; Pierce PF; Conetta B;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):437-43. PubMed ID: 15987289
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.
Gupta AK; Surprenant MS; Kempers SE; Pariser DM; Rensfeldt K; Tavakkol A
J Am Acad Dermatol; 2021 Jul; 85(1):95-104. PubMed ID: 32585278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
